AGIOS PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $239.57 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2024-02-15
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-12-31 was $82.95M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-09-30 was $104.07M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-06-30 was $82.81M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-03-31 was -$26.57M, a 137.35% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2023 was $239.57M, a 1.52% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2022 was $243.26M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2021 was -$554.16M, a 823.93% decline from fiscal 2020.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2020 was $76.55M, a 16.42% decline from fiscal 2019.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-12-31 | $239.57M 10-K · filed 2024-02-15 | |||
| 2022-12-31 | $82.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $187.02M derived: sum of 2 quarters · filed 2024-02-15 | $269.83M derived: sum of 3 quarters · filed 2024-02-15 | $243.26M 10-K · filed 2024-02-15 |
| 2022-09-30 | $104.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $186.88M derived: sum of 2 quarters · filed 2022-11-03 | $160.31M 10-Q · filed 2022-11-03 | $65.89M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $82.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $56.24M 10-Q · filed 2022-08-04 | -$38.18M derived: sum of 3 quarters · filed 2024-02-15 | -$270.91M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$26.57M 10-Q · filed 2022-05-05 | -$120.99M derived: sum of 2 quarters · filed 2024-02-15 | -$353.72M derived: sum of 3 quarters · filed 2024-02-15 | -$651.87M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$94.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$327.15M derived: sum of 2 quarters · filed 2024-02-15 | -$625.30M derived: sum of 3 quarters · filed 2024-02-15 | -$554.16M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$232.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$530.88M derived: sum of 2 quarters · filed 2022-11-03 | -$459.74M 10-Q · filed 2022-11-03 | -$387.89M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$298.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$227.01M 10-Q · filed 2022-08-04 | -$155.16M derived: sum of 3 quarters · filed 2023-02-23 | -$281.40M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $71.14M 10-Q · filed 2022-05-05 | $142.99M derived: sum of 2 quarters · filed 2023-02-23 | $16.75M derived: sum of 3 quarters · filed 2023-02-23 | $39.30M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $71.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$54.39M derived: sum of 2 quarters · filed 2023-02-23 | -$31.84M derived: sum of 3 quarters · filed 2023-02-23 | $76.55M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$126.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$103.70M derived: sum of 2 quarters · filed 2021-11-03 | $4.70M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $22.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $130.94M 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $108.39M 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | $91.58M 10-K · filed 2022-02-24 | |||
| 2017-03-31 | $109.55M 10-Q · filed 2017-05-04 | $32.03M derived: sum of 2 quarters · filed 2017-05-04 | -$30.71M derived: sum of 3 quarters · filed 2017-05-04 | $5.03M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-12-31 | -$77.52M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | -$140.26M derived: sum of 2 quarters · filed 2017-02-16 | -$104.52M derived: sum of 3 quarters · filed 2017-02-16 | -$119.35M 10-K · filed 2017-02-16 |
| 2016-09-30 | -$62.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$27.00M derived: sum of 2 quarters · filed 2016-11-03 | -$41.83M 10-Q · filed 2016-11-03 | -$20.87M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-06-30 | $35.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $20.91M 10-Q · filed 2016-08-08 | $41.87M derived: sum of 3 quarters · filed 2017-05-04 | $72.03M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-03-31 | -$14.83M 10-Q · filed 2017-05-04 | $6.13M derived: sum of 2 quarters · filed 2017-05-04 | $36.29M derived: sum of 3 quarters · filed 2017-05-04 | $68.49M derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | $20.96M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $51.12M derived: sum of 2 quarters · filed 2017-02-16 | $83.32M derived: sum of 3 quarters · filed 2017-02-16 | $128.31M 10-K · filed 2017-02-16 |
| 2015-09-30 | $30.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $62.36M derived: sum of 2 quarters · filed 2016-11-03 | $107.35M 10-Q · filed 2016-11-03 | -$179.95M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-30 | $32.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $77.19M 10-Q · filed 2016-08-08 | -$210.11M derived: sum of 3 quarters · filed 2017-02-16 | -$225.21M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-31 | $44.99M 10-Q · filed 2016-05-09 | -$242.31M derived: sum of 2 quarters · filed 2017-02-16 | -$257.41M derived: sum of 3 quarters · filed 2017-02-16 | -$276.08M derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | -$287.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | -$302.40M derived: sum of 2 quarters · filed 2017-02-16 | -$321.07M derived: sum of 3 quarters · filed 2017-02-16 | -$333.34M 10-K · filed 2017-02-16 |
| 2014-09-30 | -$15.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$33.77M derived: sum of 2 quarters · filed 2015-11-06 | -$46.03M 10-Q · filed 2015-11-06 | -$66.44M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | -$18.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$30.94M 10-Q · filed 2015-08-07 | -$51.35M derived: sum of 3 quarters · filed 2016-02-26 | -$132.07M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | -$12.27M 10-Q · filed 2015-05-11 | -$32.67M derived: sum of 2 quarters · filed 2016-02-26 | -$113.40M derived: sum of 3 quarters · filed 2016-02-26 | -$103.52M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | -$20.41M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$101.13M derived: sum of 2 quarters · filed 2016-02-26 | -$91.25M derived: sum of 3 quarters · filed 2016-02-26 | -$87.22M 10-K · filed 2016-02-26 |
| 2013-09-30 | -$80.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$70.84M derived: sum of 2 quarters · filed 2014-11-07 | -$66.81M 10-Q · filed 2014-11-07 | |
| 2013-06-30 | $9.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $13.91M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $4.04M 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | $23.04M 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |